ABN – Tekmira Pharamceuticals has halted its clinical drug trials for its experimental treatment for Ebola after discovering the drug was ineffective.
Patients taking part in the clinical trials for the TKM-Ebola-Guinea drug will not be enrolled onto Phase II.
The future of the drug will be dependent on the results of the company’s data analysis of the trial, which will be released as soon as possible.
Trials started in Sierra Leone in March where the disease affected more than 12,000 people.
Study chief investigator Dr Peter Horby said: “It is a great tribute to the team in Sierra Leone that the trial has been run so efficiently and that we now have substantial experience on the use of TKM-Ebola-Guinea in patients with Ebola.
“While the trial has reached a statistical endpoint, final conclusions on the efficacy and tolerability of the drug must await full analysis of the data.”